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Background: Breast cancer is the most common malignancy in women world-wide. Triple negative breast cancer
(TNBC) is a highly aggressive subtype that lacks expression of hormone receptors for estrogen, progesterone and
human epidermal growth factor 2; and is associated with a high propensity for metastatic spread. Several studies
have identified critical roles for microRNAs in breast cancer, but the role of two critical enzymes involved in
microRNA biogenesis, Dicer and Drosha, is not well understood, particularly with respect to metastatic progression
in this subtype.
Methods: We examined the expression of Dicer and Drosha in a series of invasive 35 TNBCs with matched normal
adjacent tissues (n = 18) and lymph node metastases (n = 15) using semi-quantitative real time RT-PCR. The
relationship of their expression with clinical features including age at diagnosis, lymph node positivity and tumour
size was analysed.
Results: We report that Dicer was significantly decreased while Drosha was significantly increased in tumours when
compared to normal adjacent tissues. While there was no difference in Drosha expression in lymph node
metastases when compared to the primary tumour, Dicer was significantly increased. There was no correlation
between the expression of either Dicer or Drosha to age at diagnosis, lymph node positivity and tumour size.
Conclusions: In conclusion, Dicer and Drosha are dysregulated in TNBC and matched lymph node metastases
however, the clinical relevance of this is still not known. The altered expression of Dicer and Drosha may serve as
markers for disrupted miRNA biogenesis in TNBC.
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Breast cancer is the most common malignancy that de-
velops in women worldwide, responsible for the highest
cancer-associated death rates [1]. Triple negative breast
cancer (TNBC) represents an important clinical subtype,
characterised by an absence of estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth
factor receptor 2 (HER2) and which therefore lack com-
mon targets used for anti-hormone therapies [2,3]. Al-
though TNBCs comprise only a small percentage of all* Correspondence: Kelly.Kiejda@newcastle.edu.au
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distribution, and reproduction in any mediumbreast cancers diagnosed (10-24%), patients are of younger
age, tend to develop tumours of larger size, and have an
increased likelihood of distant metastasis and death
within 5 years of diagnosis [2,3]. Thus, TNBCs represent
a major problem for which targeted therapies are cur-
rently not available.
microRNAs (miRNAs) are a class of small (~22 nucle-
otides) non-coding RNAs that control gene expression
by targeting mRNAs and triggering either translational
repression or RNA degradation [4]. Several studies have
identified critical roles for miRNAs in breast cancer diag-
nosis and prognosis [5-10]. Two enzymes, Drosha and
Dicer, are pivotal in the processing of pri-miRNA into ma-
ture double stranded miRNA fragments [4]. Drosha is a
nuclear enzyme that cleaves primary miRNA transcriptsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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RNA precursors that contain a 3’ overhang, known as pre-
miRNA [11]. The pre-miRNAs are then exported to the
cytoplasm where they are cleaved by Dicer into mature
double-stranded miRNA fragments of approximately 22
nucleotides in length [11]. Numerous studies have investi-
gated the role of Drosha and Dicer in a variety of cancers
including breast, lung, ovarian, colorectal and esophageal
cancer [12-23]. In breast cancer, both Dicer and Drosha
expression have been reported to be reduced when
compared to normal adjacent tissue [18-23]. Reduced
expression of Dicer has been associated with high grade,
shorter metastasis-free survival and with the TNBC sub-
type [19,21-23]. A reduction in the expression of Drosha
in breast cancer has been reported to be associated with
high grade and shorter disease free survival [18,21].
However, there have been no studies regarding the asso-
ciation of Dicer or Drosha with clinical features or their
role in breast cancer progression in TNBC, a highly
aggressive breast cancer subtype with a propensity for
metastatic spread.
In this study we examined the expression of Dicer and
Drosha in a series of 35 TNBCs with matched normal
adjacent tissues (n = 18) and lymph node (LN) metasta-
ses (n = 15) using semi-quantitative real time RT-PCR.
The correlation of their expression with clinical features
including age at diagnosis, LN positivity and tumour size
was also examined.Methods
Study cohort
Thirty-five formalin-fixed paraffin-embedded (FFPE) in-
vasive ductal carcinomas (IDCs) were obtained from
Hunter Area Pathology Service, John Hunter Hospital,
Newcastle, Australia. All patients were diagnosed with
grade 3 IDC between the years of 2004-2009, and were
negative for ER, PR and HER2 as assessed through
routine diagnostic pathology. The demographic details
of this cohort have previously been published [24].
Areas of tissue representing histologically normal adja-
cent breast tissue (NAT, where available, n = 18), IDC
and LN metastases (n = 15) were identified and con-
firmed by a pathologist. Micrometastases (<2 mm) were
not used. A 1.5 mm punch biopsy was used to punch
cores from the paraffin blocks using haemotoxylin and
eosin stained sections of the same sample for guidance.
Tumour volume in the core biopsy was >70% of the
total. This study complies with the Helsinki Declaration
with ethical approval from the Hunter New England
Human Research Ethics Committee (Approval number:
09/05/20/5.02). In accordance with the National State-
ment on Ethical Conduct in Research Involving Humans,
a waiver of consent was granted for this study.Extraction of RNA
Total RNA was extracted using the miRNeasy FFPE kit
(Qiagen, Doncaster, VIC, Australia). RNA was quantified
using the Quant-it RiboGreen RNA Assay kit (Invitrogen,
Mulgrave, VIC, Australia) and purity assessed by A260/A280
and A260/230 ratios (>1.8) using the Nanodrop. The RNA
integrity of selected samples was analysed using the 2100
Bioanalyser and the RNA 6000 Nano kit (Agilent Tech-
nologies, Mulgrave, VIC, Australia).
Semi-quantitative real-time PCR
Total RNA (250 ng) was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Mulgrave, VIC, Australia) which utilises
random hexamers in the reverse transcription reaction.
Real-time PCR analysis was performed in triplicate using
TaqMan® Universal PCR mix (Life Technologies) accord-
ing to the manufacturers’ instructions, with results quanti-
fied on a 7500 real-time PCR system (Life Technologies)
as described previously [25]. The expression of Dicer
(Hs00998588_g1), Drosha (Hs00203008_m1) and β2-
Microglobulin (Hs99999907_m1) were quantified using
Taqman Gene Expression Assays (Life Technologies).
The relative expression of the Dicer and Drosha were
normalised to β2-Microglobulin (ΔCt) and expressed as
the fold change as described previously [25]. We have veri-
fied that β2-Microglobulin is equally expressed among the
different tissues analysed in this study (NAT, IDC, LN)
(Additional file 1: Table S1 and Additional file 1: Figure S1).
Statistical analysis
The normality of the data distribution was tested using a
D’Agostino and Pearson Omnibus test. The values were
found not to have been sampled from a Gaussian distribu-
tion and thus, non-parametric statistical tests were used to
compare the data. A two-tailed Mann-Whitney U test was
used to determine if there was a statistically significant dif-
ference in the expression of Dicer and Drosha between any
two subgroups. The Wilcoxon matched-pairs signed rank
test was used to determine if there was a statistically signifi-
cant difference in the expression of Dicer and Drosha be-
tween matched pairs. The Kruskal-Wallis rank test followed
by a Dunn’s Multiple Correction test was used to determine
the statistical significance of Dicer and Drosha expression
between multiple (>2) subgroups. Analysis of the correl-
ation between Dicer and Drosha expression and clinical
parameters was performed using Spearman’s correlation
test. All analysis was performed using GraphPad Prism
(version 5.04, GraphPad software Inc., La Jolla, CA, USA).
Results
Drosha is more highly expressed than Dicer in TNBC
The expression of Dicer and Drosha was quantitated in
all 35 TNBCs by real time RT-PCR. The relative mRNA
Figure 1 Dicer and Drosha expression in triple negative breast cancer. A) Relative quantification of Dicer and Drosha by real-time RT-PCR
in tumour (n = 35) samples. B) The correlation between Dicer and Drosha expression levels. C) Relative quantification of Dicer and Drosha by
real-time RT-PCR in all NAT (n = 18) and IDC (n = 35) samples. D) Relative quantification of Dicer and Drosha by real-time RT-PCR in matched NAT
(n = 18) and IDC (n = 18) samples. E) Correlation between Dicer and Drosha fold change in IDC versus NAT samples. Results are shown as the
relative normalised expression (target/β2-Microglobulin) of the target (2-ΔCt). Boxes (A) represent the median ± interquartile range. Horizontal line
(C) represents the median ± interquartile range. Decreased and increased expression in tumour versus normal (D) is shown in green and red
respectively. *p < 0.0001, **p = 0.0039, ***p = 0.0432, #p = 0.0235.
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Figure 2 Dicer and Drosha expression in tumours and lymph
node metastases. Relative quantification of A) Dicer and B) Drosha
by real-time RT-PCR in NAT from LN- patients versus matched
LN- tumours (IDC- vs NAT-, n = 5), NAT from LN + patients versus
matched LN + tumours (IDC + vs NAT+, n = 13) and LN metastases
versus matched LN + tumours (LN vs IDC+, n = 15). Results are
shown as the fold change (2-ΔΔCt) of Dicer and Drosha expression in
matched cases, *p = 0.0202.
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p < 0.0001) than the expression of Dicer (Figure 1A). In
addition, the expression of Dicer and Drosha were found
to be highly correlated in tumours (Figure 1B, rs = 0.5384,
p = 0.0008). This is consistent with the findings of Passon
et al. and Dedes et al., who also found Dicer and Drosha
expression to be correlated in breast cancer [21,23].
Dicer is decreased while Drosha is increased in TNBC
when compared to matched normal tissue
There have only been two studies that have examined
the relative expression of both Dicer and Drosha in
TNBC in relation to the normal breast [21,23]. However,
they compared their tumour specimens to a small num-
ber of unmatched normal breast tissues (n = 6, n = 10)
that were derived from reduction mammoplasty. Con-
trasting results were found with Passon et al. concluding
that there was no significant difference in the expression
of these two genes in the normal breast compared to
TNBC [23] and Dedes et al., found a significant down-
regulation for Dicer only [21]. Given the heterogeneous
nature of the breast, we examined Dicer and Drosha ex-
pression in TNBC compared to matched normal adjacent
tissues (NAT). Initially, we examined all NAT (n = 18)
compared to all tumours (n = 35) and found the expres-
sion of Dicer and Drosha was highly variable in both tis-
sue types (Figure 1C). Dicer expression was found to be
significantly reduced in tumour tissue compared to NAT
in the unmatched analysis (p = 0.0039), while no difference
was observed for Drosha expression (Figure 1C). This is
consistent with the results of Dedes et al. [21].
We next examined the expression of Dicer and Drosha
in the matched NAT-tumour pairs (n = 18). Again, Dicer
was found to be significantly reduced in 13/18 (72%)
tumours compared to NAT (Figure 1D, p = 0.0432). In
contrast, Drosha was significantly increased in 14/18 (78%)
tumours when compared to matched NAT (Figure 1D,
p = 0.0235). Given the contrasting results, we hypothesised
that decreased Dicer expression may be compensating for
increased Drosha expression in these tissues and examined
whether the fold change in Dicer and Drosha expression in
tumour versus NAT was correlated. We found no correl-
ation between Dicer and Drosha fold induction in tumour
compared to NAT (Figure 1E, p = 0.1105).
Dicer and Drosha are not associated with clinical features
of TNBC
There are mixed reports regarding whether Dicer and
Drosha are associated with disease progression in breast
cancer [18,19,21,22]. However, the relationship of these
genes to progression and other clinical features in the
TNBC subtype has not been studied. We examined the
relative expression of Dicer and Drosha in matched LN
metastases to determine if there was a progressive lossin Dicer or gain in Drosha from normal to tumour to
metastasis. We compared this to the expression of these
genes in tumours that were LN negative. The fold change
in the expression of Dicer and Drosha in tumour com-
pared to NAT was similar in LN + and LN- tumours
(compare IDC- vs NAT- with IDC + vs NAT+, Figure 2).
The fold increase in Drosha expression when LN metasta-
ses were compared to their matched primary tumour (LN
vs IDC+) was not different to the increase observed in
tumour versus NAT (IDC + vs NAT+) (Figure 2B). In con-
trast, there was a significant increase in Dicer expression
when LN metastases were compared to their matched pri-
mary tumour (LN vs IDC+, p = 0.0202, Figure 2A). This
suggests that while there is a decrease in Dicer in the pro-
gression from normal to tumour, there is a subsequent
increase following metastases to the lymph node. The
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served in 12/15 tumours analysed.
We examined whether the expression of Dicer or
Drosha in tumours was associated with clinical features
of breast cancer. We found no correlation of either
Drosha or Dicer expression with age at diagnosis, tumour
size or the number of positive lymph nodes (Table 1).
Discussion
Dicer and Drosha have been reported to be dysregulated
in TNBC [21,23]. However, these studies used very few
normal tissues in their analysis and the correlation with
LN metastases was not examined. This study aimed to
evaluate whether the relative expression of Dicer and
Drosha was altered in TNBC and whether it was associ-
ated with clinical features and progression to LN metas-
tases in this subtype.
Our results have shown that Drosha was expressed at
significantly higher levels than Dicer in TNBC and that
the expression of these two genes was highly correlated
with one another, in agreement with the results of
Passon et al. and Dedes et al. [21,23]. Decreased ex-
pression of Dicer has been noted in several cancers,
while increased expression has been observed in ovar-
ian, prostate and colorectal cancer [12-14]. We ob-
served a significant decrease in Dicer expression in
breast cancer when compared to matched NAT. The
proportion of cases with decreased Dicer expression in
this study (72%) is similar to that previously reported
by Passon et al. (61.3%) and Dedes et al. (77.7%)
[21,23]. In contrast, we observed a significant increase
in Drosha expression in 78% of the tumour tissues ana-
lysed when compared to matched NAT. This confirms
previous findings that Drosha is increased in TNBC
[23]. The relevance of increased Drosha expression and
decreased Dicer expression in TNBC is not known at
present. It is possible that Dicer expression becomesTable 1 Correlation between Dicer and Drosha expression















*Values represent Spearman’s rank correlation coefficient.decreased as a result of increased Drosha expression to
limit miRNA biogenesis, thereby reducing miRNA func-
tion in the breast.
Reduced Dicer expression as well as over-expression
has previously been reported to be associated with worse
prognosis in breast and colorectal cancer respectively,
indicating cancer specific differences in the prognostic
value of this gene [14,19]. Although we did not have out-
come data on the patients used in this study, we were
able to examine whether Dicer and Drosha were differ-
entially expressed in LN positive patients compared to
LN negative patients and whether this expression was
related to clinical features in the highly aggressive TNBC
subtype. While Dicer was reduced in primary breast can-
cers of both LN positive and LN negative patients; unex-
pectedly, we found its expression significantly increased
in LN metastases when compared to matched primary
tumours. However, we saw no association of either
Dicer or Drosha with clinical features including age at
diagnosis, tumour size or the number of positive lymph
nodes. This may be due to the small sample size used in
this analysis, but TNBC represents a very specific pro-
portion of all breast cancers and these specimens are
difficult to obtain. This is the only study to date that has
analysed Dicer and Drosha in TNBC samples compared
to matched normal adjacent tissue and matched lymph
node metastases.
A limitation of our study is that it was performed only
on cDNA derived from FFPE tissues. Although FFPE
tissues contain fragmented RNA, our real-time RT-PCR
assays were designed with small amplicon sizes (Dicer-
65 bp, Drosha- 66 bp and β2-Microglobulin- 75 bp) to cir-
cumvent the requirement for intact RNA. Additionally,
random hexamers were incorporated in the reverse-
transcription procedure, which do not require the RNA to
be intact, in contrast to reverse-transcription with oligo
dT. Given the inconsistent correlations between these en-
zymes at the mRNA and protein level in the literature,
and that the interpretation/quantification of Dicer and
Drosha immunohistochemical staining is problematic, we
did not perform immunohistochemical analyses on this
cohort of tumours [21,22]. Although, the sample size
used in this study is relatively small, the tumours are
homogenous with regards to size, hormone receptor
status and histological grade and this is the only study
that has analysed matched TNBC cases and lymph node
metastases.
Conclusions
This study has shown that Dicer and Drosha are dysreg-
ulated in TNBC and matched LN metastases. We have
shown that Dicer is down-regulated, while Drosha is up-
regulated in primary breast cancers compared to NAT.
There was no difference in Drosha expression in lymph
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however, Dicer was significantly increased. This suggests
that while there is a decrease in Dicer in the progression
from NAT to tumour, there is a subsequent increase fol-
lowing metastases to the lymph node. The clinical rele-
vance of this is under investigation.
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β2-Microglobulin in NAT, IDC and LNs. Figure S1. The expression of
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interquartile ranges. No significant difference (p>0.05) was observed
between the sub-groups (Kruskal-Wallis rank test followed by a Dunn’s
Multiple Correction test).
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